Does Sanofi (SNY) Have a Long Runway for Future Growth?

2 days ago 3

Soumya Eswaran

Thu, January 15, 2026 astatine 7:12 AM CST 3 min read

Oakmark Funds, advised by Harris Associates, released its “Oakmark Global Select Fund” fourth-quarter 2025 capitalist letter. It is simply a non-diversified money that focuses connected semipermanent superior appreciation by investing successful communal stocks of U.S. and non-U.S. companies. A transcript of the missive tin beryllium downloaded here. In the 4th quarter, the money (Investor Class) delivered a instrumentality of 2.91%, lagging down the benchmark, the MSCI World Index’s 3.12% gain. Healthcare and financials were the apical show contributors astatine the assemblage level, portion the user discretionary and user staples detracted from performance. In addition, you tin cheque the Fund’s apical 5 holdings to find its champion picks for 2025.

In its fourth-quarter 2025 capitalist letter, Oakmark Global Select Fund highlighted stocks specified arsenic Sanofi (NASDAQ:SNY). Headquartered successful Paris, France, Sanofi (NASDAQ:SNY) is simply a healthcare and pharmaceutical institution that engages successful the manufacturing and selling of therapeutic solutions. On January 14, 2026, Sanofi (NYSE:SNY) banal closed astatine $47.89 per share. One-month instrumentality of Sanofi (NYSE:SNY) was -0.21%, and its shares mislaid 5.62% of their worth implicit the past 52 weeks. Sanofi (NYSE:SNY) has a marketplace capitalization of $116.027 billion.

Oakmark Global Select Fund stated the pursuing regarding Sanofi (NYSE:SNY) successful its 4th fourth 2025 capitalist letter:

"Sanofi (NYSE:SNY) is simply a planetary pharmaceutical institution processing biologics, vaccines and healthcare solutions to forestall and dainty a wide scope of conditions successful immunology, hemophilia, uncommon diseases and wide medicine. The institution is best-known for its artifact buster drug, Dupixent, a fast-growing biologic that provides doctors with a single, versatile therapy for aggregate inflammatory conditions, combining beardown efficacy with a cleanable information profile. Beyond Dupixent, we deliberation determination is simply a batch to beryllium excited astir arsenic absorption has prioritized innovation by aggressively investing successful probe and improvement to cultivate a pipeline of promising products. Despite beardown fundamentals, the banal has been weighed down by a volatile twelvemonth for the vaccine market, capitalist concerns astir patent cliffs and minimal worth ascription to its pipeline. This created the accidental for america to put successful a institution we judge is improving, with a agelong runway for aboriginal maturation arsenic vaccine markets normalize and caller merchandise imaginable is realized."

Is Sanofi (SNY)the Best Gene-Editing Stock to Buy?

Sanofi (NYSE:SNY) is not connected our database of 30 Most Popular Stocks Among Hedge Funds. According to our database, 32 hedge money portfolios held Sanofi (NYSE:SNY) astatine the extremity of the 3rd quarter, up from 24 successful the erstwhile quarter. While we admit the imaginable of Sanofi (NYSE:SNY) arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.